iCamuno starts with induced pluripotent stem cells (iPSCs) and uses cutting-edge technologies such as gene editing, and algorithm-driven cellular differentiation to empower cells. Guided by the philosophy of “demand-oriented, patient-centered”, we are changing the face of tumor immunotherapy and reg...See more
Headquarter China |
Year founded 2021 (3 years) |
Funding status Private |
Company type SME |
Research Fellow
CMC Director